PreveCeutical Medical (Seite 9)
eröffnet am 04.10.18 20:07:39 von
neuester Beitrag 06.05.24 23:44:20 von
neuester Beitrag 06.05.24 23:44:20 von
Beiträge: 879
ID: 1.289.874
ID: 1.289.874
Aufrufe heute: 4
Gesamt: 30.226
Gesamt: 30.226
Aktive User: 0
ISIN: CA74141E1043 · WKN: A2DU8Q · Symbol: PREV
0,0250
CAD
0,00 %
0,0000 CAD
Letzter Kurs 08.05.24 CSE
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 14,160 | +37,88 | |
| 0,7400 | +36,63 | |
| 5,1500 | +34,46 | |
| 12,470 | +22,50 | |
| 1,6300 | +20,74 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0500 | -28,32 | |
| 1,5100 | -29,44 | |
| 7,9700 | -36,75 | |
| 2,4100 | -51,51 | |
| 0,5800 | -56,72 |
Beitrag zu dieser Diskussion schreiben
Feedback
Stephen Van Deventer:
The importance of the Linker tech is that it’s a new way to link the molecules together when synthesizing the pharma ingredients. So all our molecules are now guaranteed to continue using this system. Next Generation stuff!!!
The importance of the Linker tech is that it’s a new way to link the molecules together when synthesizing the pharma ingredients. So all our molecules are now guaranteed to continue using this system. Next Generation stuff!!!
Ich habe noch einmal 40.000 Stück gesichert.
Trading Spotlight
Antwort auf Beitrag Nr.: 73.142.860 von DrMoeller am 23.01.23 13:06:30Wunderbar. Die Serie gebt weiter
Weitere sehr gute News über Patente, es lohnt noch nachzukaufen !!!
https://ceo.ca/@newsfile/preveceutical-background-ip-us-pate…
Articles@newsfile/preveceutical-background-ip-us-patent-granted-disulfide channel
0 online Today This week
by @newsfile on 23 Jan 2023, 07:00
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform technology. The US patent protects the disulfide linker platform technology, which is used in peptides forming part of PreveCeutical's BSV (blue scorpion venom) peptide program, Non-Analgesic Dynorphin (Painkiller) and D&O (Diabetes & Obesity) Gene Therapy siRNA program.
Grant of this patent is a key component, foundation and building block of PreveCeutical's IP strategy in the development of three of its four therapeutic programs.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We are very pleased with the US grant of this patent to the University of Queensland as this technology is important to PreveCeutical for possible therapies for BSV Peptides, Dynorphin Peptides, and Diabetes and Obesity Gene Therapy. This will contribute towards the US protection of the linker technology as we further develop our IP and clinical research towards the commercialization of possible therapies."
0 online Today This week
by @newsfile on 23 Jan 2023, 07:00
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform technology. The US patent protects the disulfide linker platform technology, which is used in peptides forming part of PreveCeutical's BSV (blue scorpion venom) peptide program, Non-Analgesic Dynorphin (Painkiller) and D&O (Diabetes & Obesity) Gene Therapy siRNA program.
Grant of this patent is a key component, foundation and building block of PreveCeutical's IP strategy in the development of three of its four therapeutic programs.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We are very pleased with the US grant of this patent to the University of Queensland as this technology is important to PreveCeutical for possible therapies for BSV Peptides, Dynorphin Peptides, and Diabetes and Obesity Gene Therapy. This will contribute towards the US protection of the linker technology as we further develop our IP and clinical research towards the commercialization of possible therapies."
Antwort auf Beitrag Nr.: 73.106.559 von jetset0711 am 17.01.23 14:31:29Der Newsflow müsste weiter gehen.
Antwort auf Beitrag Nr.: 73.105.908 von Hamburgerjung89 am 17.01.23 13:18:38Schauen wir mal wann die Rakete zündet! Zeit wäre es! ✌️😃
Durchsuchen
